Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05570149 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Study acronym: EMBRACE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2024 to Dec 31, 2025
    • Study completion date: Dec 2026 to Dec 31, 2026
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 10 more changesShow less
    • Primary completion date: Dec 31, 2023 to Dec 2024
    • Primary endpoints: 1 to 4
    • Study sites: 0 to 1
    • Study completion date: Dec 31, 2026 to Dec 2026
    • Interventions: Eptinezumab (Drug) to Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution (Drug)
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: 1 to 26
    • Study description shortened, about 93 words
    • Publications: 4 to 5
    • Study title shortened, about 3 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Trial Details
NCT Number NCT05570149
Lead Sponsor IRCCS San Raffaele Roma
Conditions
(from sponsor)		 Migraine Disorders
Related terms Migraine Disorders
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov